Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

被引：4

作者：

Gilbert, Lucy ^{[1
,2
,3
]}

Ramanakumar, Agnihotram, V ^{[4
]}

Festa, Maria Carolina ^{[1
,2
]}

Jardon, Kris ^{[1
,2
,3
]}

Zeng, Xing ^{[1
,2
,3
]}

Martins, Claudia ^{[1
,2
,3
]}

Shbat, Layla ^{[1
,2
]}

Alsoud, Marwa Abo ^{[1
,2
]}

Borod, Manuel ^{[3
,5
]}

Wolfson, Michael ^{[6
]}

Papaioannou, Ioanna ^{[7
]}

Basso, Olga ^{[4
,8
]}

Sampalis, John ^{[7
,9
]}

机构：

[1] McGill Univ, Gynecol Canc Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[2] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[3] McGill Univ, Dept Oncol, 5100 Maisonneuve Blvd West, Montreal, PQ H4A 3T2, Canada

[4] McGill Univ, Res Inst, Hlth Ctr, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[5] McGill Univ, Support & Palliat Care Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[6] Univ Ottawa, Dept Epidemiol & Community Med, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3, Canada

[7] JSS Med Res, 9400 Henri Bourassa West, Montreal, PQ H4S 1N8, Canada

[8] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, 1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada

[9] McGill Univ, Fac Med, Dept Surg, Div Surg Res, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 08期

关键词：

cytotoxic chemotherapy; healthcare costs; recurrent high-grade serous ovarian cancer; MAINTENANCE THERAPY; DOUBLE-BLIND; SURVIVAL; CARCINOMA; OUTCOMES; WOMEN;

D O I：

10.2217/cer-2020-0032

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

引用

页码：537 / 551

页数：15

共 50 条

[21] High-grade serous ovarian cancer: the clone wars
Aleksander Salomon-Perzyński
Magdalena Salomon-Perzyńska
Bogdan Michalski
Violetta Skrzypulec-Plinta
Archives of Gynecology and Obstetrics, 2017, 295 : 569 - 576
[22] High-grade serous ovarian cancer: the clone wars
Salomon-Perzynski, Aleksander
Salomon-Perzynska, Magdalena
Michalski, Bogdan
Skrzypulec-Plinta, Violetta
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
[23] The role of Apela in high-grade serous ovarian cancer
Daily, Laura R.
Ganguly, Debolina
Hayes, D. Neil
Wang, Yinan
Sims, Michelle M.
Cheng, Jinjun
ElNaggar, Adam C.
Pfeffer, Lawrence M.
CANCER RESEARCH, 2018, 78 (13)
[24] Drugs Repurposing in High-Grade Serous Ovarian Cancer
Torralba, Manuel
Farra, Rossella
Maddaloni, Marianna
Grassi, Mario
Dapas, Barbara
Grassi, Gabriele
CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
[25] Transcriptomic profiles of response to neoadjuvant chemotherapy in patients with high-grade serous ovarian cancer
Lee, Sanghoon
Zhao, Li
Fleming, Nicole D.
Celestino, Joseph
Hajek, Richard A.
Morgan, Margaret B.
Liu, Yan
Westin, Shannon N.
Jazaeri, Amir A.
Liu, Jinsong
Zhang, Jianhua
Futreal, P. Andrew
Sood, Anil K.
CANCER RESEARCH, 2022, 82 (12)
[26] Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer (HGSOC)
LaVigne, K.
Benhamida, J.
Young, J.
Zivanovic, O.
Chi, D. S.
Snyder, A.
Hollmann, T.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 76 - 76
[27] EXAMINING THE REAL-WORLD HEALTHCARE COSTS OF TREATING CHRONIC WOUNDS
Landsman, A.
Masturzo, A.
Barbul, A.
VALUE IN HEALTH, 2019, 22 : S213 - S213
[28] Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
Arend, Rebecca C.
Londono, Angelina I.
Montgomery, Allison M.
Smith, Haller J.
Dobbin, Zachary C.
Katre, Ashwini A.
Martinez, Alba
Yang, Eddy S.
Alvarez, Ronald D.
Huh, Warner K.
Bevis, Kerri S.
Straughn, J. Michael, Jr.
Estes, Jacob M.
Novak, Lea
Crossman, David K.
Cooper, Sara J.
Landen, Charles N.
Leath, Charles A., III
MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 813 - 824
[29] Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma
Montgomery, A. M.
Crossman, D. K.
Yang, E. S.
Alvarez, R. D.
Huh, W. K.
Bevis, K. S.
Straughn, J. M., Jr.
Leath, C. A., III
Arend, R. C.
GYNECOLOGIC ONCOLOGY, 2017, 145 : 12 - 13
[30] Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer.
Chen, Xiaoxiang
Ni, Jing
Xu, Xia
Guo, Wenwen
Zhao, Qian
Cheng, Xianzhong
Zhou, Rui
Gu, Hongyuan
Chen, Chen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →